Dan Costin, MD

Articles by Dan Costin, MD

Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.

Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option

ByDan Costin, MD

October 5th 2026

Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.

Latest Updated Articles

Trending on CancerNetwork

How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?

Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

How Is Subcutaneous Administration Changing Oncology Care Delivery?

FDA OKs Pirtobrutinib in Frontline CLL/SLL